

Proteoglycan-4 Inhibits TGF- β Induced Differentiation of Synovial Fibroblasts into Myofibroblasts in a CD44-Dependent Manner

Marwa Qadri¹, Gregory D. Jay², Ling Zhang², Tannin A. Schmidt³, Khaled A. Elsaid¹

¹Chapman University School of Pharmacy, Irvine, CA, ²Department of Emergency Medicine, Rhode Island Hospital, Providence, RI, ³Biomedical Engineering Department, School of Dental Medicine, University of Connecticut, Farmington, CT



Objective: to study the role of PRG4 in modulating myofibroblast differentiation of OA fibroblast-like synoviocytes (OA FLS) and whether this effect is mediated by interaction with CD44.

Hypothesis: PRG4 inhibits TGF- β induced differentiation of synovial fibroblasts into myofibroblasts via a CD44-dependent mechanism.

Methods:

Impact of proteoglycan-4 (PRG4) treatment on TGF- β 1 induced α -SMA expression, production and stress fiber formation in OA FLS. (results shown in fig. 1)

ACTA2 expression and α -SMA content in synovia from 2 months old wildtype (*Prg4*^{+/+}), 2 months old knockout (*Prg4*^{-/-}), 2 and 9 months old gene-trap (*Prg4*^{GT/GT}) and 2 and 9 months old recombined gene-trap (*Prg4*^{GTR/GTR}) mice. (results shown in fig. 2)

Interaction of rhodamine-labeled recombinant human proteoglycan-4 (rhPRG4) with OA FLS and the role of CD44 receptor in mediating reduction in TGF- β 1 induced ACTA2 expression. (results shown in fig. 3)

Conclusions:

- Synovial PRG4 and HA treatments reduced α -SMA expression, production and stress fiber formation in TGF- β stimulated OA FLS.
- ACTA2 expression was higher in *Prg4*^{-/-} synovia compared to *Prg4*^{+/+} synovia and older gene-trap animals had higher ACTA2 expression and re-expression of Prg4 reduced ACTA2 expression.
- CD44 neutralization reversed the reduction in ACTA2 expression by rhPRG4 in TGF- β 1 stimulated OA FLS.




Fig. 1 Impact of proteoglycan-4 (PRG4) treatment on TGF- β 1 induced α -SMA expression, production and stress fiber formation in OA FLS. * $p < 0.001$; ** $p < 0.01$. **A.** PRG4 (100 μ g/ml) and hyaluronic acid (HA; 100 μ g/ml) treatments reduced ACTA2 expression in OA FLS. **B.** Representative immunofluorescence images of α -SMA (green), α -tubulin (red) and DAPI (blue) of OA FLS following TGF- β 1 treatment \pm PRG4 or HA. Arrows point to formation of stress fibers characteristic of myofibroblasts. **C.** PRG4 and HA treatments reduced α -SMA corrected total cell fluorescence in TGF- β 1 stimulated OA FLS. Scale=50 μ m.




Fig. 2 ACTA2 expression and α -SMA content in synovia from 2 months old wildtype (*Prg4*^{+/+}), 2 months old knockout (*Prg4*^{-/-}), 2 and 9 months old gene-trap (*Prg4*^{GT/GT}) and 2 and 9 months old recombined gene-trap (*Prg4*^{GTR/GTR}) mice (n=5 in each group). * $p < 0.001$; *** $p < 0.05$. **A.** ACTA2 expression was higher in *Prg4*^{-/-} synovia. **B.** Representative images showing enhanced α -SMA (green) immunostaining in *Prg4*^{-/-} synovia (white arrows) and none in *Prg4*^{+/+} synovia. **C.** ACTA2 expression was higher in 9 month old *Prg4*^{GT/GT} synovia than 2 months old animals and recombination reduced ACTA2 expression. **D.** Representative images showing enhanced α -SMA (green) immunostaining in synovia from 2 and 9 months old *Prg4*^{GT/GT} (white arrows) and recombination reduced α -SMA staining. Scale=100 μ m.




Fig. 3 Interaction of rhodamine-labeled recombinant human proteoglycan-4 (rhPRG4) with OA FLS and the role of CD44 receptor in mediating reduction in TGF- β 1 induced ACTA2 expression. * $p < 0.001$; *** $p < 0.05$. **A.** Representative images depicting intracellular localization of rhodamine-rhPRG4 (red) in OA FLS following a 30 min incubation \pm anti-CD44 or isotype control (IC) antibodies. Arrows point to intracellular localization of rhPRG4. **B.** Corrected total cell fluorescence was lower in rhPRG4+anti-CD44 treated OA FLS compared to rhPRG4 alone or rhPRG4+IC treated OA FLS. **C.** ACTA2 expression in rhPRG4+anti-CD44 antibody treated OA FLS was higher than rhPRG4 alone or rhPRG4+IC antibody treated OA FLS. Scale=50 μ m.